Anemia Drugs News
Drugs
> Anemia DrugsAnemia Drugs News is an EIN News Service for health professionals. Constantly updated news and information about health.
- FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 20 Nov 2009 14:36 GMT
... 13 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), ... pain, muscle and joint pain, muscle cramps, anemia, and fatigue. There was a statistically significant ... medical need, and if the benefit of treatment will outweigh the potential increased risk. Lysteda ...
- Lysteda tablets to treat menorrhagia approved by the FDA 24 Nov 2009 07:16 GMT
... Heavy Menstrual Bleeding The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), ... pain, muscle and joint pain, muscle cramps, anemia, and fatigue. There was a statistically significant ... medical need, and if the benefit of treatment will outweigh the potential increased risk. Lysteda ...
- Lysteda tablets to treat menorrhagia approved by FDA 16 Nov 2009 06:35 GMT
... Heavy Menstrual Bleeding The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), ... pain, muscle and joint pain, muscle cramps, anemia, and fatigue. There was a statistically significant ... medical need, and if the benefit of treatment will outweigh the potential increased risk. Lysteda ...
- Range of Cancer-Fighting Agents Get FDA Nod 23 Nov 2009 13:32 GMT
... types of cancer. (pazopanib) is the sixth drug to be approved for kidney cancer since ... approval for use in patients for the treatment of cutaneous T-cell lymphoma (CTCL) who have ... anorexia in 1 study, and nausea, fatigue, anemia, thrombocytopenia, ECG T-wave changes, neutropenia, and lymphopenia ...
- American Heart Association Late-breaking Clinical Trial Report: Risks of Anemia Drug Outweigh Benefits in Cardiovascular Disease Patients With Diabetes and Kidney Disease 16 Nov 2009 13:32 GMT
... Association Late-breaking Clinical Trial Report: Risks of Anemia Drug Outweigh Benefits in Cardiovascular Disease Patients With ... does not improve patient cardiovascular outcomes. - Treatment with darbepoetin alfa in patients with type ...
- American Heart Association Late-breaking Clinical Trial Report: Risks of Anemia Drug Outweigh Benefits in Cardiovascular 16 Nov 2009 13:30 GMT
... - Risks of an anemia drug appear to outweigh its benefits among diabetic ... does not improve patient cardiovascular outcomes. - Treatment with darbepoetin alfa in patients with type ...
- Advances in Molecular Drug Development Highlighted 16 Nov 2009 20:13 GMT
... seen a major expansion in the cancer drug pipeline and studies are continually underway to ... arsenal of drugs and create more effective treatments and targeted therapies for patients. To highlight ... minimize blood system side effects, such as anemia," said Sean McDermott, Ph.D., research investigator in ...
- AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline 17 Nov 2009 11:16 GMT
... seen a major expansion in the cancer drug pipeline and studies are continually underway to ... arsenal of drugs and create more effective treatments and targeted therapies for patients. To highlight ... minimize blood system side effects, such as anemia," said Sean McDermott, Ph.D., research investigator in ...
- FDA approves Lysteda for treating menorrhagia 16 Nov 2009 14:57 GMT
... oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual ... pain, muscle and joint pain, muscle cramps, anemia, and fatigue. Concomitant use of hormonal contraceptives ...
- Correcting Iron Helps in CHF, Anemia or Not 17 Nov 2009 18:31 GMT
... feel better even in the absence of anemia, according to a randomized trial. Intravenous iron (ferric carboxymaltose, Injectafer) increased the ... next step is to make sure long-term treatment is safe." Determining what effect correction of ...
- Xanodyne Announces FDA Approval of Lysteda(TM) (Tranexamic Acid) for Treatment of Women with Heavy M 16 Nov 2009 13:52 GMT
... FDA Approval of Lysteda(TM) (Tranexamic Acid) for Treatment of Women with Heavy Menstrual Bleeding Xanodyne ... oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women ... pain, muscle and joint pain, muscle cramps, anemia, and fatigue. Concomitant use of hormonal contraceptives ...
- Xanodyne Announces FDA Approval of Lysteda(TM) (Tranexamic Acid) for Treatment of Women with Heavy Menstrual Bleeding 16 Nov 2009 13:52 GMT
... FDA Approval of Lysteda(TM) (Tranexamic Acid) for Treatment of Women with Heavy Menstrual Bleeding First-in-class ... oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women ... pain, muscle and joint pain, muscle cramps, anemia, and fatigue. Concomitant use of hormonal contraceptives ...
- Xanodyne Announces FDA Approval of Lysteda (Tranexamic Acid) for Treatment of Women with Heavy Menstrual Bleeding 16 Nov 2009 15:14 GMT
... FDA Approval of Lysteda (Tranexamic Acid) for Treatment of Women with Heavy Menstrual Bleeding First-in-class ... oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women ... pain, muscle and joint pain, muscle cramps, anemia, and fatigue. Concomitant use of hormonal contraceptives ...
- American Heart Association Late-Breaking Clinical Trial Report: Study Finds no Significant Cardiovascular Differences Between More Aggressive or Restrictive Post-Operative Treatment of Anemia 16 Nov 2009 13:32 GMT
... American Heart Association Late-Breaking Clinical Trial Report: Study Finds no Significant Cardiovascular Differences ... Differences Between More Aggressive or Restrictive Post-Operative Treatment of Anemia - A liberal red blood cell (RBC) ...
- American Heart Association Late-Breaking Clinical Trial Report: Study Finds no Significant Cardiovascular Differences Be 16 Nov 2009 13:30 GMT
... (RBC) transfusion strategy to aggressively treat post-operative anemia in asymptomatic elderly patients undergoing hip fracture ... g/dL), researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific ... statistically significant benefit of the more aggressive treatment for CVD outcomes. "Postoperative anemia is common ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
nytimes.com:
ap.org:
bbc.co.uk:
reuters.com:
msnbc.msn.com:
healthday.com: